Looking at Gefitinib (Iressa), Pharma14’s proprietary Market Opportunity Locator indicates that this oncological medicine has generic registrations in various European countries and Canada.
Although Gefitinib has seen recent generic marketing launches, there still remain quite a few European countries and in the US where Astra Zeneca's Iressa is the only competitor on the market.
Countries' such as Belgium, Brazil, Greece, Italy, US and UK to name a few, still have not seen any generic launch in Gefitinib.
Pharma14's "Market opportunity locator" is a live proprietary platform that tracks all registrations in 39 countries giving members of our platform direct insight when new generics are registered as well as when they appear on the market.
Sample data: Gefitinib. Competitive landscape.